CMS is proposing temporary expansions of Medicare and Medicaid coverage of GLP-1s for obesity through demonstration programs CMS initially proposed a two-step approach to expanding coverage of GLP-1s for obesity in Medicare a temporary payment demonstration for 2026, known as the Medicare GLP-1 Bridge, and a new Center for Medicare and Medicaid Innovation (CMMI) model, known as the BALANCE Model, that was originally scheduled to begin in January 2027 and end in December 2031
If youre considering weight loss treatments like Semaglutide or Tirzepatide, you may be unsure about which medication is best suited to your needs
Like most GLP-1 medications, the most common side effects are gastrointestinal, such as nausea, especially when starting
Combination Therapy Changes the Equation If you are also taking glipizide, glimepiride, or insulin, your hypoglycemia risk is meaningfully higher
While ED medication can improve the quality and duration of erections, it does not directly contribute to penile growth